Randomized Phase 2 Study on the Relationship Between Circulating VEGF and Weekly or Every-Four-Week Zometa [zoledronic acid] in Breast Cancer Patients With Bone Metastases.

Trial Profile

Randomized Phase 2 Study on the Relationship Between Circulating VEGF and Weekly or Every-Four-Week Zometa [zoledronic acid] in Breast Cancer Patients With Bone Metastases.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Advanced breast cancer; Breast cancer; Cancer metastases
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Oct 2009 Status changed from active, no longer recruiting to completed.
    • 12 Oct 2009 Results have been presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top